It seems my industry colleagues have been wrongly optimistic and also hyper cynical. At least that is the bottom line of the read I get in comparing the analysis of the 2nd annual Semaphore Confidence Survey with last year’s results. And some people have very...
The Valley of Death for a Life Sciences company is that space, as coined by the NCI’s Director of Small Business Innovation Research Programs Michael Weingarten, between a Phase 2 SBIR grant and the commercial success of the technology that is being funded and...
Blog Series 3 of 4 Pipeline Interviews: The Missing Piece At this point, you may be thinking, “The analysis addressed the overall market size, the potential penetration of the market, and the company’s likely share. Shouldn’t that be enough?”...
Blog series 4 of 4 Conducting Pipeline Interviews There are two keys to conducting Pipeline Interviews. First, make sure to interview accounts at a variety of stages in the pipeline. The reasons why prospects don’t progress past the first meeting usually concern the...
I live in Massachusetts and let’s face it; we live in what is perceived to be a high tax state. Whether this belief is true or not we share that belief of high taxes with California, New York, New Jersey and Michigan. On the other hand Florida, Texas and North...
I field calls from GPs and CEOs all the time. Invariably they are doing a deal, whether investment or acquisition, and need either verification that the technology and/or markets targeted are real or a product exists and someone wishes to buy it in the future. Less...
